{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-9CMYHIX8/1df2a5a1-3710-48e7-9ecf-cf6c6847a964/PDF","dcterms:extent":"213 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-9CMYHIX8/ebc6577d-6793-43a4-bbd8-fb1c04d10a87/TEXT","dcterms:extent":"30 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-9CMYHIX8","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2018","dc:creator":["Roškar, Robert","Temova Rakuša, Žane"],"dc:format":[{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"letnik:69"},{"@xml:lang":"sl","#text":"str. 236-242"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:4559473","URN:URN:NBN:SI:doc-9CMYHIX8"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"Biološka zdravila"},{"@xml:lang":"en","#text":"drug"},{"@xml:lang":"sl","#text":"nestabilnost"},{"@xml:lang":"sl","#text":"stabilizacija"},{"@xml:lang":"sl","#text":"terapevtski proteini"},{"@xml:lang":"sl","#text":"Zdravila"},{"@rdf:resource":"http://www.wikidata.org/entity/Q405372"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Stabilnost terapevtskih proteinov| Stability of therapeutic proteins|"},"dc:description":[{"@xml:lang":"sl","#text":"Biopharmaceuticals represent an important class of pharmaceuticals that are widely used in clinical practice. Compared to traditional synthetic active ingredients, peptide and protein molecules are substantially larger with more complex structure. Because of their unique three dimensional structures and many functional groups, therapeutic proteins are susceptible to various degradation mechanisms, which can be divided in two general classes: chemical and physical instability. The most common form of physical instability is denaturation with subsequent aggregation, precipitation and surface adsorption. Chemical instabilities include oxidation, deamidation and other less frequent reactions. Both types of instability can increase the likelihood of adverse immunogenic effects and/or result in a decreased biological activity. Therefore, characterization of instability mechanisms is a critical part of quality assurance process. The article summarizes the most common degradation mechanisms and factors, which affect proteins stability and also discusses appropriate approaches towards protein stabilization"},{"@xml:lang":"sl","#text":"Sodobna biološka zdravila pokrivajo širok spekter uporabe v terapiji različnih bolezni. V primerjavi s tradicionalnimi učinkovinami sinteznega izvora so učinkovine peptidne in proteinske narave bistveno večje in bolj zapletene molekule. Zaradi številnih funkcionalnih skupin in različnih nivojev strukture so terapevtski proteini izpostavljeni različnim oblikam nestabilnosti, ki jih v splošnem delimo na fizikalne in kemijske. Najpogostejša oblika fizikalne nestabilnosti je denaturacija proteinov s kasnejšo agregacijo, precipitacijo in adsorpcijo na površine. Kemijska nestabilnost proteina pa vključuje oksidacijo, deamidacijo in druge manj pogoste reakcije. Obe obliki nestabilnosti imata lahko za posledico zmanjšanje biološke aktivnosti in/ali povečanje imunogenosti, zato je v okviru zagotavljanja kakovosti potrebno proučiti mehanizme nestabilnosti. V prispevku povzemamo najpogostejše mehanizme nestabilnosti in dejavnike, ki povzročajo nestabilnost, ter predlagamo ustrezne pristope k stabilizaciji proteinov"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-9CMYHIX8","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-9CMYHIX8"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-9CMYHIX8/1df2a5a1-3710-48e7-9ecf-cf6c6847a964/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-9CMYHIX8/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-9CMYHIX8"}}}}